• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pancreatic cancer: Exosomes for targeting KRAS in the treatment of pancreatic cancer.

作者信息

Buscail Louis

机构信息

Department of Gastroenterology, Centre of Clinical Investigation for Biotherapy and INSERM U1037, Rangueil Hospital, Centre Hospitalier Universitaire of Toulouse and University of Toulouse 3, 1 avenue Jean Poulhès, TSA 50032, 31059 Toulouse, France.

出版信息

Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):636-638. doi: 10.1038/nrgastro.2017.113. Epub 2017 Sep 6.

DOI:10.1038/nrgastro.2017.113
PMID:28874835
Abstract
摘要

相似文献

1
Pancreatic cancer: Exosomes for targeting KRAS in the treatment of pancreatic cancer.胰腺癌：用于治疗胰腺癌中靶向KRAS的外泌体
Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):636-638. doi: 10.1038/nrgastro.2017.113. Epub 2017 Sep 6.
2
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.外泌体有助于在胰腺癌中对致癌性KRAS进行治疗靶向。
Nature. 2017 Jun 22;546(7659):498-503. doi: 10.1038/nature22341. Epub 2017 Jun 7.
3
Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.致癌性KRAS与胰腺癌发生中的表皮生长因子受体环——与许可节点的联系
Small GTPases. 2018 Nov 2;9(6):457-464. doi: 10.1080/21541248.2016.1262935. Epub 2017 Jan 20.
4
Generation and testing of clinical-grade exosomes for pancreatic cancer.生成和测试胰腺癌的临床级别的外泌体。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.99263.
5
α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.α-倒捻子素包载 PLGA 纳米粒通过靶向人源和转基因（Kras(G12D), 和 Kras(G12D)/tp53R270H) 小鼠的肿瘤干细胞抑制胰腺癌发生。
Sci Rep. 2016 Sep 14;6:32743. doi: 10.1038/srep32743.
6
Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer.靶向整合素连接激酶以抑制胰腺癌中的致癌KRAS信号传导。
Small GTPases. 2018 Nov 2;9(6):452-456. doi: 10.1080/21541248.2016.1251383. Epub 2016 Dec 9.
7
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.尼古丁通过 Gata6 依赖性去分化胰腺腺泡细胞促进 KRAS 诱导的胰腺癌的发生和进展。
Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12.
8
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.靶向KRAS用于胰腺癌的诊断、预后评估及治疗：希望与现实
Eur J Cancer. 2016 Feb;54:75-83. doi: 10.1016/j.ejca.2015.11.012. Epub 2015 Dec 28.
9
[Kras oncogene and pancreatic cancer: thirty years after].[Kras癌基因与胰腺癌：三十年之后]
Med Sci (Paris). 2013 Nov;29(11):991-7. doi: 10.1051/medsci/20132911015. Epub 2013 Nov 20.
10
p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.胰腺癌中 p21 激活激酶信号：肿瘤生物学和免疫调节的新见解。
World J Gastroenterol. 2018 Sep 7;24(33):3709-3723. doi: 10.3748/wjg.v24.i33.3709.

引用本文的文献

1
Toxoplasma gondii-Derived Exosomes: A Potential Immunostimulant and Delivery System for Tumor Immunotherapy Superior to Toxoplasma gondii.刚地弓形虫来源的外泌体：一种优于刚地弓形虫的潜在免疫刺激剂和肿瘤免疫治疗递送系统。
Int J Nanomedicine. 2024 Nov 22;19:12421-12438. doi: 10.2147/IJN.S483626. eCollection 2024.
2
Identification of MYEOV-Associated Gene Network as a Potential Therapeutic Target in Pancreatic Cancer.鉴定与MYEOV相关的基因网络作为胰腺癌潜在的治疗靶点
Cancers (Basel). 2022 Nov 4;14(21):5439. doi: 10.3390/cancers14215439.
3
Protective role of small extracellular vesicles derived from HUVECs treated with AGEs in diabetic vascular calcification.

本文引用的文献

1
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.外泌体有助于在胰腺癌中对致癌性KRAS进行治疗靶向。
Nature. 2017 Jun 22;546(7659):498-503. doi: 10.1038/nature22341. Epub 2017 Jun 7.
2
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.KRAS G12D突变亚型是晚期胰腺腺癌的一个预后因素。
Clin Transl Gastroenterol. 2016 Mar 24;7(3):e157. doi: 10.1038/ctg.2016.18.
3
Extracellular vesicles for drug delivery.细胞外囊泡用于药物递送。
AGEs 处理后的 HUVECs 来源的小细胞外囊泡在糖尿病血管钙化中的保护作用。
J Nanobiotechnology. 2022 Jul 16;20(1):334. doi: 10.1186/s12951-022-01529-z.
4
Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.长链非编码 RNA 与肿瘤免疫微环境：生物学特性与治疗潜能
Front Immunol. 2021 Jul 6;12:697083. doi: 10.3389/fimmu.2021.697083. eCollection 2021.
5
Role of exosomes in pancreatic cancer.外泌体在胰腺癌中的作用。
Oncol Lett. 2021 Apr;21(4):298. doi: 10.3892/ol.2021.12559. Epub 2021 Feb 17.
6
BxPC-3-Derived Small Extracellular Vesicles Induce FOXP3+ Treg through ATM-AMPK-Sirtuins-Mediated FOXOs Nuclear Translocations.BxPC-3来源的小细胞外囊泡通过ATM-AMPK-沉默调节蛋白介导的FOXO核转位诱导FOXP3+调节性T细胞
iScience. 2020 Aug 21;23(8):101431. doi: 10.1016/j.isci.2020.101431. Epub 2020 Aug 2.
7
A Review on Electroporation-Based Intracellular Delivery.基于电穿孔的细胞内递药研究综述。
Molecules. 2018 Nov 21;23(11):3044. doi: 10.3390/molecules23113044.
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):148-156. doi: 10.1016/j.addr.2016.02.006. Epub 2016 Feb 27.
4
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.靶向KRAS用于胰腺癌的诊断、预后评估及治疗：希望与现实
Eur J Cancer. 2016 Feb;54:75-83. doi: 10.1016/j.ejca.2015.11.012. Epub 2015 Dec 28.
5
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.针对KRAS的RNA干扰疗法联合化疗用于局部晚期胰腺癌患者。
Oncotarget. 2015 Sep 15;6(27):24560-70. doi: 10.18632/oncotarget.4183.
6
TP53 loss creates therapeutic vulnerability in colorectal cancer.TP53缺失导致结直肠癌出现治疗易损性。
Nature. 2015 Apr 30;520(7549):697-701. doi: 10.1038/nature14418. Epub 2015 Apr 22.
7
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.预计 2030 年美国癌症发病与死亡人数：甲状腺癌、肝癌和胰腺癌带来的意外负担。
Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155.
8
Mutant KRAS is a druggable target for pancreatic cancer.KRAS 突变是胰腺癌的一个可用药靶。
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: 10.1073/pnas.1314307110. Epub 2013 Dec 2.
9
Roles for KRAS in pancreatic tumor development and progression.KRAS 在胰腺肿瘤发生和发展中的作用。
Gastroenterology. 2013 Jun;144(6):1220-9. doi: 10.1053/j.gastro.2013.01.071.
10
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.